Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Oct 18;17(10):e0274943.
doi: 10.1371/journal.pone.0274943. eCollection 2022.

Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial

Tazio Vanni  1 , Beatriz C Thomé  1 , Erin Sparrow  2 , Martin Friede  2 , Christopher B Fox  3 , Anna Marie Beckmann  3 , Chuong Huynh  4 , Gabriella Mondini  1 , Daniela H Silveira  1 , Juliana Y K Viscondi  1 , Patrícia Emilia Braga  1 , Anderson da Silva  1 , Maria da Graça Salomão  1 , Roberta O Piorelli  1 , Joane P Santos  1 , Vera Lúcia Gattás  1 , Maria Beatriz B Lucchesi  1 , Mayra M M de Oliveira  1 , Marcelo E Koike  1 , Esper G Kallas  5 , Lucia M A Campos  6 , Eduardo B Coelho  7 , Marilda A M Siqueira  8 , Cristiana C Garcia  8 , Milene Dias Miranda  8 , Terezinha M Paiva  9 , Maria do Carmo S T Timenetsky  9 , Eduardo A Adami  1 , Milena A Akamatsu  1 , Paulo Lee Ho  1 , Alexander R Precioso  1   6
Affiliations
Clinical Trial

Dose-sparing effect of two adjuvant formulations with a pandemic influenza A/H7N9 vaccine: A randomized, double-blind, placebo-controlled, phase 1 clinical trial

Tazio Vanni et al. PLoS One. .

Abstract

The emergence of potentially pandemic viruses has resulted in preparedness efforts to develop candidate vaccines and adjuvant formulations. We evaluated the dose-sparing effect and safety of two distinct squalene-based oil-in-water adjuvant emulsion formulations (IB160 and SE) with influenza A/H7N9 antigen. This phase I, randomized, double-blind, placebo-controlled, dose-finding trial (NCT03330899), enrolled 432 healthy volunteers aged 18 to 59. Participants were randomly allocated to 8 groups: 1A) IB160 + 15μg H7N9, 1B) IB160 + 7.5μg H7N9, 1C) IB160 + 3.75μg H7N9, 2A) SE + 15μg H7N9, 2B) SE + 7.5μg H7N9, 2C) SE + 3.75μg H7N9, 3) unadjuvanted vaccine 15μg H7N9 and 4) placebo. Immunogenicity was evaluated through haemagglutination inhibition (HI) and microneutralization (MN) tests. Safety was evaluated by monitoring local and systemic, solicited and unsolicited adverse events (AE) and reactions (AR) 7 and 28 days after each study injection, respectively, whereas serious adverse events (SAE) were monitored up to 194 days post-second dose. A greater increase in antibody geometric mean titers (GMT) was observed in groups receiving adjuvanted vaccines. Vaccinees receiving IB160-adjuvanted formulations showed the greatest response in group 1B, which induced an HI GMT increase of 4.7 times, HI titers ≥40 in 45.2% of participants (MN titers ≥40 in 80.8%). Vaccinees receiving SE-adjuvanted vaccines showed the greatest response in group 2A, with an HI GMT increase of 2.5 times, HI titers ≥40 in 22.9% of participants (MN titers ≥40 in 65.7%). Frequencies of AE and AR were similar among groups. Pain at the administration site and headache were the most frequent local and systemic solicited ARs. The vaccine candidates were safe and the adjuvanted formulations have a potential dose-sparing effect on immunogenicity against influenza A/H7N9. The magnitude of this effect could be further explored.

PubMed Disclaimer

Conflict of interest statement

Daniela H Silveira, Juliana Y K Viscondi, Patrícia Emilia Braga, Maria da Graça Salomão, Vera Lúcia Gattás, Maria Beatriz B Lucchesi, Mayra M M de Oliveira, Marcelo E Koike, Milena A Akamatsu and Paulo Lee Ho are employees of Instituto Butantan-Fundação Butantan. Marilda A M Siqueira, Cristiana C Garcia, and Milene D Miranda are employees of Fiocruz. Maria do Carmo S T Timenetsky and Terezinha M Paiva are employees of Instituto Adolfo Lutz. Alexander R Precioso, Tazio Vanni, Beatriz C Thomé, Roberta O Piorelli, Anderson da Silva, Eduardo A Adami, Joane P Santos, and Gabriella Mondini are former employees of Instituto Butantan-Fundação Butantan. Esper G Kallas, Lucia M A Campos, and Eduardo B Coelho received research-grant from Fundação Butantan for their roles as principal investigators. Erin Sparrow, Martin Friede, Christopher B Fox. Anna Marie Beckmann, and Chuong Huynh are scientific and financial sponsors. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. CONSORT flow diagram of participants through the study.
Fig 2
Fig 2. HI antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, intention-to-treat.
Fig 3
Fig 3. HI antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, per protocol analysis.
Fig 4
Fig 4. Association of HI seroprotection rate after 28(+7) days post 2nd dose administration with prior receipt of seasonal influenza vaccine, intention-to-treat analysis.
Fig 5
Fig 5. Association of HI seroprotection rate after 28(+7) days post 2nd dose administration with prior receipt of seasonal influenza vaccine, per protocol analysis.
Fig 6
Fig 6. MNT antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, intention-to-treat.
Fig 7
Fig 7. MNT antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, per protocol analysis.
See this image and copyright information in PMC

References

    1. Li H, Cao B. Pandemic and Avian Influenza A Viruses in Humans: Epidemiology, Virology, Clinical Characteristics, and Treatment Strategy. Clin Chest Med. 2017. Mar;38(1):59–70. doi: 10.1016/j.ccm.2016.11.005 Epub 2016 Dec 10. - DOI - PubMed
    1. Danqi B, Li Z, Liu Q, Richt JA. H7N9 avian influenza A virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs. Expert Rev Anti Infect Ther. 2017. Aug;15(8):723–727. doi: 10.1080/14787210.2017.1353419 Epub 2017 Jul 17. - DOI - PMC - PubMed
    1. Xiao YL, Ren L, Zhang X, Qi L, Kash JC, Xiao Y, et al.. Deep Sequencing of H7N9 Influenza A Viruses from 16 Infected Patients from 2013 to 2015 in Shanghai Reveals Genetic Diversity and Antigenic Drift. mSphere. 2018. Sep 19;3(5):e00462–18. doi: 10.1128/mSphereDirect.00462-18 - DOI - PMC - PubMed
    1. Lin YJ, Shih YJ, Chen CH, Fang CT. Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis. Sci Rep. 2018. Jul 30;8(1):11460. doi: 10.1038/s41598-018-29858-w - DOI - PMC - PubMed
    1. Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, et al.. DMID 13–0032 H7N9 Vaccine Study Group. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA. 2014. Oct 8;312(14):1409–19. doi: 10.1001/jama.2014.12854 - DOI - PubMed

Publication types

Associated data